Lv61
2460 积分 2023-10-18 加入
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non–small cell lung cancer
5天前
已完结
Identification of Targetable EGFR Mutations in Ovarian Cancer
5天前
已关闭
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
9天前
已关闭
Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
9天前
已完结
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
10天前
已完结
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
1个月前
已完结
Assessment of the evidence yield for the calibrated PP3/BP4 computational recommendations
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
4个月前
已完结
Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway
9个月前
已完结
皖公网安备34019202002308
